This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, to Alchem Laboratories Corporation. The contract, valued at up to $17,891,012, is to provide CRO (contract research organization) support services for NCATS's Medicinal Chemistry for Lead Optimization program. Under this multiple-award IDC, Alchem Laboratories will perform a variety of preclinical and...
Alchem Laboratories Corporation was awarded a single award indefinite delivery contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The contract has a potential value of $12,069,385 and a period of performance through April 10, 2028. The contract aims to procure analysis and synthesis of Good Manufacturing Practice and non-GMP bulk drugs and pharmaceutical formulations to support the National Cancer Institute's...
The National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, awarded a single award Indefinite Delivery Contract to Alchem Laboratories Corporation. The contract has a potential value of $7,777,665 and a period of performance from September 2017 to September 2022. Under the contract, Alchem Laboratories Corporation provides non-good manufacturing practices synthesis of small molecules to support the National Cancer Institute's...
The federal contract IDV award is for Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products for the National Center for Advancing Translational Sciences (NCATS), a civilian agency. This is a multiple award, indefinite delivery contract with a $49,885,703 ceiling value and a period of performance through July 2031. The prime contractor, Alchem Laboratories Corporation, is a for-profit pharmaceutical manufacturer that will provide a broad...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
This Indefinite Delivery Contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The $49.9 million, multiple-award IDC will provide Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products from August 2024 through July 2031. The contract aims to obtain a broad range of preclinical services...
The provided information describes a single-award Indefinite Delivery Contract (IDC) awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The prime contractor, Aapharmasyn LLC (a small disadvantaged business), will provide Experimental Therapeutics Medicinal Chemistry services with a contract ceiling of $50,000,000 and a period of performance through September 14, 2032. The contract primarily supports...
This is an Indefinite Delivery Contract (IDC) awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Advanced Bioscience Laboratories, Inc. (ABL) for Chemistry, Manufacturing and Controls (CMC) and related services to support the development of drug substances. The contract has a potential value of $49,713,679 and a period of performance from May 15, 2024 to May 14, 2031. It is a multiple award...
This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $80 million IDC is for manufacturing and characterization services for vaccines and other biologics targeting infectious diseases. Under this IDC, ABL has been issued multiple task orders for a range of...
This is a single-award Indefinite Delivery Contract (IDC) issued by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The base contract has a potential value of $124,500,000 and a period of performance through September 28, 2028. The purpose is to provide NIAID Preclinical Development Support...